A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY OF ZILOVERTAMAB VEDOTIN (MK-2140) IN COMBINATION WITH R-CHP VERSUS R-CHOP IN PARTICIPANTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (WAVELINE-010)

Registry ID

MK-2140-010

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2025-07-28

Last update

2024-12-13

Conditions

• DIFFUSE LARGE B-CELL LYMPHOMA

Related clinical trials

• Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
• AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
• A PROSPECTIVE, MULTICENTER, PHASE II TRIAL TO EVALUATE THE EFFICACY OF ZANUBRUTINIB AND TISLELIZUMAB AS WELL AS STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH PROGRESSIVE LYMPHOMA POST ANTI-CD19 CAR-T CELL THERAPY (ZETA)
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF GOLCADOMIDE PLUS R-CHOP CHEMOTHERAPY VS PLACEBO PLUS R-CHOP CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED HIGH-RISK LARGE B-CELL LYMPHOMA
• FEASIBILITY TRIAL OF GLOFITAMAB IN A RESPONSE ADAPTED APPROACH INCORPORATING INTERIM FDG PET AND CTDNA TO OPTIMIZE PRIMARY THERAPY OF DLBCL (GRAIL)
• A MULTI-CENTER SINGLE ARM PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF GENETICALLY ENGINEERED AUTOLOGOUS CELLS EXPRESSING ANTI-CD20 AND ANTI-CD19 SPECIFIC CHIMERIC ANTIGEN RECEPTOR IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA

View on source registry